A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Paul R HelftMark J Ratain

Abstract

The purpose is to determine the maximum-tolerated dose, assess the toxicities, characterize the pharmacokinetic behavior, and seek preliminary evidence of biological activity of cantuzumab mertansine when administered as a weekly i.v. infusion without interruption. Patients with incurable solid tumors that expressed the target antigen for cantuzumab mertansine, CanAg, were treated with doses of cantuzumab mertansine ranging from 40 to 138 mg/m(2). The maximum-tolerated dose was defined as the highest dose at which no more than 1 of 6 patients experienced dose-limiting toxicity. Plasma concentrations of cantuzumab mertansine and total humanized antibody were determined, and area under the plasma concentration-time curve (to the last measured concentration) was calculated. Thirty-nine patients received a total of 280 weekly doses of cantuzumab mertansine. Acute, transient elevation of the hepatic transaminases and reversible fatigue were identified as the dose-limiting toxicities at the highest dose level. The maximum-tolerated dose was determined to be 115 mg/m(2)/week. Evidence of clinical activity was noted in 3 patients. Pharmacokinetic analyses revealed that the pharmacokinetic variability was moderate, without evidence of d...Continue Reading

References

Dec 1, 1978·Cancer Treatment Reviews·B F Issell, S T Crooke
Jan 1, 1978·Journal of the National Cancer Institute·R T EaganC G Moertel
Jan 1, 1991·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·C JohanssonL Lindholm
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·C LiuR V Chari
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony W TolcherEric K Rowinsky

❮ Previous
Next ❯

Citations

Feb 19, 2005·Current Oncology Reports·Emiliano Calvo, Eric K Rowinsky
Mar 21, 2006·Pathologie-biologie·Gerhardt AttardJohann De Bono
Mar 30, 2007·Nature Clinical Practice. Oncology·Alejandro D Ricart, Anthony W Tolcher
Jun 10, 2008·The Cancer Journal·Paul J Carter, Peter D Senter
Oct 13, 2010·Molecular Cancer Therapeutics·Emin OroudjevMary Ann Jordan
Mar 1, 2011·Therapeutic Delivery·Victor S Goldmacher, Yelena V Kovtun
Feb 28, 2008·Cancer Chemotherapy and Pharmacology·Jordi RodonAnthony W Tolcher
Mar 28, 2008·Expert Opinion on Investigational Drugs·Michelle Harrison, Charles Swanton
Mar 1, 2006·Expert Opinion on Biological Therapy·Hongsheng Xie, Walter A Blättler
Jun 28, 2007·Expert Opinion on Investigational Drugs·Felix KratzAndré Warnecke
Oct 30, 2007·ChemMedChem·Felix KratzAndré Warnecke
Dec 3, 2014·Seminars in Oncology·Darshil T JhaveriElizabeth M Jaffee
Jul 16, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Véronique DiérasIan E Krop
May 18, 2017·Journal of Surgical Oncology·Jeremy KingJohn Williams
Feb 2, 2018·Journal of Applied Toxicology : JAT·Sarah TaplinRobert Johnson
May 17, 2018·Expert Review of Anticancer Therapy·Thinzar M LwinMichael Bouvet
Nov 18, 2008·Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Sep 2, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jagath R JunutulaMark X Sliwkowski
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bernard M TijinkGuus A M S van Dongen
Jul 11, 2006·Journal of Medicinal Chemistry·Wayne C WiddisonRavi V J Chari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.